Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Next Previous
X
Search
Trial Profile

An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Voruciclib (Primary) ; Vemurafenib
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Piramal Enterprises

    • Most Recent Events

    • 02 Jun 2015 Interim results (n=9) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Sep 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
    • 14 Dec 2013 New source identified and integrated (M.D. Anderson Cancer Center, 2012-1049).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top